Curated News
By: NewsRamp Editorial Staff
October 23, 2025
NanoViricides' NV-387 Shows 130% Survival Boost Against Measles
TLDR
- NanoViricides' NV-387 offers first-mover advantage as the only potential Measles treatment, positioning the company as a leader in antiviral therapeutics.
- NV-387 works through dual antiviral and anti-inflammatory mechanisms, extending survival by 130% in animal models while protecting lung tissue from damage.
- This breakthrough could save countless lives by providing the first effective treatment for Measles, reducing suffering from this dangerous viral disease.
- NanoViricides' experimental drug dramatically extended mouse survival from 7 to 17 days while preventing lung damage from Measles infection.
Impact - Why it Matters
This development represents a potential breakthrough in treating Measles, a highly contagious disease that continues to cause outbreaks worldwide despite available vaccines. The absence of any approved therapeutic for Measles means infected individuals currently receive only supportive care, with severe cases risking pneumonia, encephalitis, and death. NV-387's demonstrated ability to not only suppress the virus but also reduce inflammation-induced lung damage addresses two critical aspects of Measles pathology. For populations with limited vaccine access, immunocompromised individuals, or those who cannot receive vaccines, an effective treatment could significantly reduce mortality and long-term complications. Furthermore, the broad-spectrum potential of NV-387 against multiple respiratory viruses suggests this technology platform could transform how we approach viral outbreaks more broadly, providing crucial tools for future pandemic preparedness.
Summary
NanoViricides, Inc., a clinical-stage biotechnology company trading on the NYSE American under the symbol NNVC, has announced groundbreaking results for its lead drug candidate NV-387 against the Measles virus. In both cell culture studies and humanized animal models, NV-387 demonstrated potent antiviral effects, extending survival in infected mice by an impressive 130%—from 7.4 to 17 days. The drug's dual mechanism of action, involving direct viral suppression and mitigation of systemic and lung inflammation, resulted in reduced lung plaques, slower disease progression, and improved overall health outcomes. This development is particularly significant given that no approved drug currently exists for Measles treatment, positioning NV-387 as a potential first-in-class therapeutic candidate that could revolutionize how this contagious disease is managed.
The company's innovative approach is built upon its nanoviricide technology platform, which creates special purpose nanomaterials for antiviral therapy. NanoViricides operates through a strategic partnership with TheraCour Pharma, Inc., holding exclusive licenses for developing drugs against numerous viral diseases. Beyond Measles, the company is advancing NV-387 as a broad-spectrum antiviral for respiratory syncytial virus (RSV), COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's pipeline also includes NV-HHV-1 for Shingles treatment and development programs targeting herpes, eye viral diseases, HIV, Hepatitis C, and Ebola virus, among others. As the company moves toward Phase II human clinical trials for NV-387, these promising Measles results validate their platform technology and approach to antiviral drug development.
BioMedWire, the specialized communications platform that published this news, serves as part of the Dynamic Brand Portfolio within the InvestorBrandNetwork, providing comprehensive distribution and enhancement services for biomedical and biotechnology companies. The platform's extensive reach ensures that breakthrough developments like NanoViricides' Measles treatment progress receive appropriate visibility among investors, medical professionals, and the broader public. As NanoViricides continues to advance its clinical programs, the company remains focused on leveraging its proprietary technology to address significant unmet medical needs in antiviral therapy, though it appropriately notes the inherent risks and lengthy timelines typical of pharmaceutical development.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' NV-387 Shows 130% Survival Boost Against Measles
